Journal of Clinical Pediatrics >
Effect of ketogenic diet on epilepsy with genetic etiology
Received date: 2021-10-08
Online published: 2022-12-06
Objective To analyze the clinical efficacy of ketogenic diet in the treatment of epilepsy with genetic etiology. Methods The clinical characteristics, ketogenic diet efficacy and prognosis of 10 epilepsy patients with genetic etiology treated in Wuxi Children's Hospital from April 2017 to March 2021 were retrospectively analyzed. Results here were 4 boys and 6 girls. The age of onset was 3 days to 16 months, and the age of ketogenic diet treatment ranged from 2 months to 12 years. The birth history was normal in each patient, and there was no abnormality in blood biochemistry, cranial MRI and hematuria genetic metabolism screening. SCN1A gene variation was found in 5 cases, and SLC2A1 gene variation was found in 2 cases. The other 3 cases had SCN2A, KIF1A and PIGA gene variation, respectively. During the follow-up period of 6 months to 4 years and 5 months after ketogenic diet, 4 cases had seizure free, including 2 cases of SLC2A1 variation and 2 cases of SCN2A and PIGA variation. Three patients with SCN1A variation had seizure reduction of more than 50%, and the other two patients with SCN1A variation had seizure reduction of less than 50%. The seizures of one child were significantly reduced after the addition of perampanel. The children with KIF1A gene variation had no significant improvement in seizures after ketogenic diet. Conclusions Ketogenic diet has a significant effect on some patients with refractory epilepsy, especially those with SLC2A1, SCN2A, PIGA and SCN1A variation. Identification of pathogenic genes is helpful to predict the efficacy of ketogenic diet.
Key words： ketogenic diet; epilepsy; gene variation
Xiaoyue HU , Miao JING , Yanping WANG , Ying HUA . Effect of ketogenic diet on epilepsy with genetic etiology[J]. Journal of Clinical Pediatrics, 2022 , 40(12) : 934 -938 . DOI: 10.12372/jcp.2022.21e1415
| [1] | 郁莉斐, 张玉琴, 廖建湘, 等. 葡萄糖转运体1缺陷综合征疾病特征及生酮饮食治疗多中心临床研究[J]. 中华儿科杂志, 2020, 58(11): 881-886. |
| [2] | 刘家雯, 丁鑫, 操德智, 等. 生酮饮食治疗药物难治性Dravet综合征的疗效和安全性的前瞻性对照研究[J]. 中华实用儿科临床杂志, 2019, 34(15): 1160-1165. |
| [3] | Schoeler NE, Leu C, Balestrini S, et al. Genome-wide association study: exploring the genetic basis for responsiveness to ketogenic dietary therapies for drug-resistant epilepsy[J]. Epilepsia, 2018, 59(8): 1557-1566. |
| [4] | Ko A, Jung DE, Kim SH, et al. The efficacy of ketogenic diet for specific genetic mutation in developmental and epileptic encephalopathy[J]. Front Neurol, 2018, 9: 530. |
| [5] | Rogawski MA, L?scher W, Rho JM. Mechanisms of action of antiseizure drugs and the ketogenic diet[J]. Cold Spring Harb Perspect Med, 2016, 6(5): a022780. |
| [6] | Schoeler NE, Cross JH, Sander JW, et al. Can we predict a favourable response to ketogenic diet therapies for drug‐resistant epilepsy?[J]. Epilepsy Res, 2013, 106(1-2): 1-16. |
| [7] | 中国医师协会神经内科医师分会儿童神经专业委员会, 中华医学会儿科学分会神经学组. 生酮饮食治疗儿童癫痫性脑病循证指南[J]. 中华实用儿科临床杂志, 2019, 34(12): 881-888. |
| [8] | Yoshitomi S, Takahashi Y, Yamaguchi T, et al. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome[J]. Epilepsy Res, 2019, 154: 34-38. |
| [9] | Gauthier AC, Manganas LN, Mattson RH. A novel inherited SCN1A mutation associated with GEFS+ in benign and encephalopathic epilepsy[J]. J Clin Neurosci, 2017, 40: 82-84. |
| [10] | 刘晓军, 韦新平, 吴波, 等. 离子通道基因变异致早发癫痫性脑病17例临床特征和基因变异分析[J]. 中华实用儿科临床杂志, 2019, 34 (12): 918-921. |
| [11] | Miao P, Tang S, Ye J, et al. Electrophysiological features: The next precise step for SCN2A developmental epileptic encephalopathy[J]. Mol Genet Genomic Med, 2020, 8(7): e1250. |
| [12] | Tian X, Zhang Y, Zhang J, et al. Ketogenic diet in infants with early-onset epileptic encephalopathy and SCN2A mutation[J]. Yonsei Med J, 2021, 62(4): 370-373. |
| [13] | Turkdogan D, Thomas G, Demirel B. Ketogenic diet as a successful early treatment modality for SCN2A mutation[J]. Brain Dev, 2019, 41(4): 389-391. |
| [14] | Kim HJ, Yang D, Kim SH, et al. The phenotype and treatment of SCN2A‐related developmental and epileptic encephalopathy[J]. Epileptic Disord, 2020, 22(5): 563-570. |
| [15] | Markus Wolff, Katrine M Johannesen, Ulrikev B S Hedrich, et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain, 2017, 140(5): 1316-1336. |
| [16] | Vreugdenhil M, Bruehl C, Voskuyl RA, et al. Poly-unsaturated fatty acids modulate sodium and calcium currents in CA1 neurons[J]. Proc Natl Acad Sci USA, 1996, 93(22): 12559-12563. |
| [17] | Jiao X, Xue J, Gong P, et al. Analyzing clinical and genetic characteristics of a cohort with multiple congenital anomalies-hypotonia-seizures syndrome (MCAHS)[J]. Orphanet J Rare Dis, 2020, 15(1): 78. |
| [18] | Joshi C, Kolbe DL, Mansilla MA, et al Ketogenic diet-a novel treatment for early epileptic encephalopathy due to PIGA deficiency[J]. Brain Dev, 2016, 38(9): 848-851. |
| [19] | Chiyonobu T, Inoue N, Morimoto M, et al. Glyco-sylphosphatidylinositol (GPI) anchor deficiency caused by mutations in PIGW is associated with West syndrome and hyperphosphatasia with mental retardation syndrome[J]. J Med Genet, 2014, 51(3): 203-207. |
| [20] | Langlois S, Tarailo-Graovac M, Sayson B, et al. De novo dominant variants affecting the motor domain of KIF1A are a cause of PEHO syndrome[J]. Eur J Hum Genet, 2016, 24(6): 949-953. |
| [21] | Jagadish S, Payne ET, Wong-Kisiel L, et al. The Ketogenic and Modified Atkin's diet therapy for children with refractory epilepsy of genetic etiology[J]. Pediatr Neurol, 2019, 94: 32-37. |
/
| 〈 |
|
〉 |
